T-cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial - PubMed
12 hours ago
- #Pancreatic cancer
- #T-cell therapy
- #KRAS G12V
- T-cell receptor gene therapy targeting KRAS G12V was tested in a phase 1/2 clinical trial for advanced pancreatic cancer.
- Five patients with recurrent pancreatic cancer received autologous T cells engineered to target KRAS G12V.
- Three patients received multiple infusions, with primary endpoints being safety and objective response rate.
- Most common grade 3+ adverse event was hematologic toxicity due to lymphodepletion.
- One patient achieved a complete response lasting 5.5 months, while two had short-term stable disease.
- TCR-T cells were detected in peripheral blood of four patients one month post-first infusion.
- No clinical responses were observed with TCR-T retreatment.
- Hyper-acute rejection occurred in two patients after retreatment, likely due to persistent antibodies against the engineered TCR.
- Study highlights safety, therapeutic potential, and challenges of repeat TCR-T infusions for KRAS G12V pancreatic cancer.